Propanc Health Group Corporation — FY2016 Form 10-K
Reporting period: Fiscal year ended June 30, 2016; filed September 28, 2016. The request labels the period “2015 Q4,” but the filing covers FY2016, not a standalone 2015 quarter. Amounts below are U.S. dollars unless stated otherwise.
Business context
Propanc is a pre-revenue, development-stage biotechnology company developing pro-enzyme cancer treatments, principally PRP, for solid tumors including pancreatic, colorectal and ovarian cancers. PRP remained in preclinical development at year-end; the company had no marketed products and had not begun formal clinical trials. Its claims of potential efficacy are based on laboratory and animal work and historical compassionate-use experience, not controlled clinical evidence.
Financial performance and liquidity
| Metric | FY2016 / June 30, 2016 | FY2015 / June 30, 2015 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $6.90 million | $1.71 million |
| Operating loss | $6.90 million | $1.71 million |
| Net loss | $9.41 million | $3.41 million |
| Research and development expense | $1.45 million | $134,319 |
| Net cash used in operating activities | $4.50 million | $1.43 million |
Gross margin is not meaningful because there was no revenue. Net loss per share was reported as $0.02 in both years, while weighted-average shares increased to 487.1 million from 177.6 million. FY2016 net loss included $4.49 million of interest expense, including $3.53 million of debt-discount amortization, and a $670,893 loss on debt settlements; a $2.74 million gain from changes in derivative fair value partially offset expenses.
At June 30, 2016, cash was $121,070, current assets $362,767, current liabilities $2.94 million, and working capital deficit $2.58 million. Total assets were $379,142 and stockholders’ deficit was $2.57 million. Convertible notes and accrued interest were reported at $1.20 million net of discounts and premiums; derivative liabilities totaled approximately $1.05 million. The auditor cited substantial doubt about the company’s ability to continue as a going concern. Management stated it lacked sufficient cash to meet obligations over the next 12 months and needed additional financing. No off-balance-sheet arrangements were reported.
Changes versus FY2015
- Net loss rose by approximately $6.00 million, and operating cash use more than tripled.
- R&D spending increased by approximately $1.31 million, primarily for animal efficacy work and preparation of manufacturing, toxicology and other preclinical activities.
- Administration expense increased to $5.43 million from $1.57 million, mainly reflecting stock-based compensation, legal, investor-relations and capital-raising costs. Stock-option expense was $1.72 million; the filing also identifies substantial option-related compensation in administration expense.
- Common shares outstanding rose from 347.4 million at June 30, 2015 to 728.6 million at June 30, 2016. The filing reports 789.7 million outstanding as of September 26, 2016.
- Financing cash inflows were $4.54 million, principally from convertible promissory notes. This funding came with dilution, variable conversion features and related derivative accounting.
Outlook, financing, risks and unusual items
- Management planned additional manufacturing and preclinical work through September 2017, estimating costs of approximately $1.60 million for manufacturing/preclinical development and $730,000 for clinical-trial preparation. It anticipated initiating a Phase I study in Q4 2017 and estimated about $900,000 for that study; it projected a Phase IIa proof-of-concept milestone in approximately three years, subject to funding, regulatory approval and results.
- The filing describes differing proposed first-in-human approaches: one section refers to a Phase I study in advanced cancer patients, while another proposes initial single- and multiple-dose studies in healthy male subjects. These are plans, not assured milestones.
- After year-end, Delafield financing terms were amended, including an extension of a debenture’s maturity to February 28, 2017 and issuance of warrants for up to 240 million shares. A further $150,000 loan was agreed in exchange for a $165,000 convertible debenture. The conversion terms can adjust downward with the share price, creating potential dilution. These post-year-end arrangements are not June 30, 2016 balance-sheet amounts.
- After year-end, the company also entered a manufacturing agreement with Q-Biologicals, anticipating $2.5 million to $5.0 million of payments over five years, with most expected in the first two years and an approximately $144,000 prepayment. The prepayment is non-refundable if the agreement is terminated early.
- The company paid $612,000 to settle the Typenex note and related litigation in May 2016, recording a corresponding loss. It also settled a JMJ matter for $90,000 in December 2015, including a $58,893 settlement loss.
- Key risks include continued financing needs and going-concern uncertainty; no clinical proof of safety or efficacy; regulatory, manufacturing, patent and commercialization uncertainty; reliance on contractors and key personnel; potential dilution from convertible securities, warrants and options; and limited trading liquidity. The company reported ineffective disclosure controls and internal control over financial reporting, citing the absence of an audit-committee financial expert, limited accounting expertise and inadequate segregation of duties.
- Related-party matters include a five-year office lease with an entity owned by the CEO and his wife, employment of the CEO’s wife, and significant compensation and option awards to the CEO and a director. The CEO received 71.5 million options, and the director received the same number; total option grants were 143 million at $0.03 per share.
Investor verification checklist
- Confirm current cash, working-capital position, going-concern status and the company’s ability to fund planned development.
- Review the latest outstanding share count, convertible balances and conversion prices, warrant terms, and potential dilution from the 240 million Delafield warrants and other securities.
- Check whether planned manufacturing, toxicology and clinical milestones were completed, and reconcile the filing’s different proposed Phase I populations and timing.
- Assess the strength and status of patent protection by jurisdiction, and distinguish granted patents from applications or preliminary patentability indications.
- Verify progress in remediating material weaknesses and review subsequent related-party payments, financing amendments and manufacturing commitments.